Search Videos and More

Showing 25 - 36 of 364 results

Previous| 1... 2 | 3 | 4 ...31 |Next


Dana-Farber Research Publication 12.1.2022 News

Dana-Farber Research Publication 12.1.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
American Society of Hematology (ASH) 2023 Symposium

American Society of Hematology (ASH) 2023

Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.
San Antonio Breast Cancer Symposium (SABCS) 2023 Symposium

San Antonio Breast Cancer Symposium (SABCS) 2023

2023 Updates in Neuro-Oncology News

2023 Updates in Neuro-Oncology

Please join us on Zoom for a free symposium on the latest advances in neuro-oncology. Through lecture and discussion, Harvard Medical School faculty will consider how to apply recent clinical research advances to improve the care and outcomes of patients with brain tumors.
Dana-Farber Research Publication 11.15.2022 News

Dana-Farber Research Publication 11.15.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
ESMO Congress 2023 Research Highlights Symposium

ESMO Congress 2023 Research Highlights

Lung, kidney, and neuroendocrine tumor cancer studies led by Dana-Farber presented at ESMO Congress 2023.
Dana-Farber Research Publication 11.01.2023 News

Dana-Farber Research Publication 11.01.2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer Document

Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
Dana-Farber Research Publication 10.15.2022 News

Dana-Farber Research Publication 10.15.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News

Dana-Farber Research Publication 8.15.2021

Read more about the highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors. 
Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker News

Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker

Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.
Dana-Farber Research Publication 10.1.2023 News

Dana-Farber Research Publication 10.1.2023

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors.

Showing 25 - 36 of 364 results

Previous| 1... 2 | 3 | 4 ...31 |Next